Exhibit 15.1
AWARENESS LETTER FROM GRANT THORNTON LLP
Raptor Pharmaceutical Corp.
5 Hamilton Landing, Suite 160
Novato, CA 94949
We have reviewed, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the unaudited condensed consolidated interim financial information of Raptor Pharmaceutical Corp. and subsidiaries as of March 31, 2013 and for the three month period then ended, as indicated in our report dated March 17, 2014; because we did not perform an audit, we expressed no opinion on that information.
We are aware that our report referred to above, which is included in your Quarterly Report on Form 10-Q/A for the quarter ended March 31, 2013, is incorporated by reference in Registration Statements on Forms S-3 (File Nos. 333-179215, 333-162430, 333-163274, and 333-173720) and Forms S-8 (File Nos. 333-190806, 333-173719, 333-166813, 333-163124, 333-151859, 333-141738, 333-138368, 333-118729, 333-103129, 333-98245 and 333-4088).
We also are aware that the aforementioned report, pursuant to Rule 436(c) under the Securities Act of 1933, is not considered a part of the Registration Statement prepared or certified by an accountant within the meaning of Sections 7 and 11 of that Act.
/s/ Grant Thornton LLP
San Francisco, California
May 12, 2014